Oral ribavirin for prevention of severe liver disease caused by hepatitis C virus during allogeneic bone marrow transplantation

Clinical Infectious Diseases

Volumn 23, Issue 1, 1996, Pages 167-169

  Ljungman, P ^a   Andersson, J ^b   Aschan, J ^b   Bjorkstrand B ^b   Hagglund H ^b   Lonnqvist B ^b   Ringden, O ^b   Winiarski, J ^b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYCLOSPORIN; METHOTREXATE; RIBAVIRIN; VIRUS RNA;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; CASE REPORT; DOSE RESPONSE; DRUG SAFETY; GRAFT VERSUS HOST REACTION; HEMOLYSIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER DISEASE; NOTE; ORAL DRUG ADMINISTRATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCHOOL CHILD; VEIN OCCLUSION;

EID: 0029809777     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/23.1.167     Document Type: Note

References (16)

1. McDonald GB, Hinds MS, Fisher LD, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993;118:255-67.
2. Frickhofen N, Wiesneth M, Jainta C, et al. Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood 1994;83:1998-2004.
3. Ljungman P, Hagglund H, Lönnqvist B, Sonnerborg A, Ringdén O. Hepatitis C virus as a risk factor for the development of veno-occlusive disease of the liver. Blood 1994;84:1349-50.
4. Norol F, Roche B, Girardin MF, et al. Hepatitis C virus infection and allogeneic bone marrow transplantation. Transplantation 1994;57:393-7.
5. Reichard O, Andersson J, Schwarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet 1991;337:1058-60.
6. Camps J, García N, Riezu-Boj J, Civeira M, Prieto J. Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon. J Hepatol 1993:19:408-12.
7. Ringdén O, Remberger M, Persson U, et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR compatible unrelated bone marrow donors as with HLA-identical siblings. Bone Marrow Transplant 1995;15:619-26.
8. Yun Z-B, Lindh G, Weiland O, Johansson B, Sonnerborg A. Detection of hepatitis C virus (HCV) RNA by PCR related to HCV antibodies in serum and liver histology in Swedish blood donors. J Med Virol 1993;39:57-61.
9. Locasciulli A, Pontisso P, Alberti A, Bacigalupo A, Ljungman P, Frickhofen N. The genotype of hepatitis C virus does not affect severity of liver disease after bone marrow transplantation. Blood 1995;85:2640.
10. Chen PM, Liu JH, Fan FS, et al. Liver disease after bone marrow transplantation - the Taiwan experience. Transplantation 1995;59:1139-43.
11. Kolho E, Ruutu P, Ruutu T. Hepatitis C infection in BMT patients. Bone Marrow Transplant 1993;11:119-23.
12. Johnson K. Ribavirin treatment of arenavirus, hantavirus, pneumo-virus, and paramyxovirus disease: topical and systemic therapy. In: Mills J, Corey L, eds. Antiviral chemotherapy. New directions for clinical application and research. Englewood Cliffs, New Jersey: Prentice Hall, 1993:229-49.
13. Reichard O, Yun Z-B, Sönnerborg A, Weiland O. Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C. J Med Virol 1993;41:99-102.
14. Maruta A, Kanamori H, Fukawa H, et al. Liver function tests of recipients with hepatitis C virus infection after bone marrow transplantation. Bone Marrow Transplant 1994;13:417-22.
15. Ljungman P, Johansson N, Aschan J, et al. Long-term effects of hepatitis C virus infection in allogeneic bone marrow transplant recipients. Blood 1995;86:1614-8.
16. Fan FS, Tzeng CH, Hsiao KJ, Hu ST, Liu WT, Chen PM. Withdrawal of immunosuppressive therapy in allogeneic bone marrow transplantation reactivates chronic viral hepatitis C. Bone Marrow Transplant 1991;8:417-20.